Vertex Pharmaceuticals Inc/ US92532F1003 /
| 2024-05-08 10:00:00 PM | Chg. +8.5800 | Volume | Bid11:30:50 AM | Ask11:30:50 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 418.8200USD | +2.09% | 1.65 mill. Turnover: 398.47 mill. |
415.0000Bid Size: 100 | 442.0000Ask Size: 100 | 108.08 bill.USD | - | 29.81 |
Assets
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 433.6000 | 696.9000 | 715.8120 | 697.7150 | 698.3620 | ||||||
| Intangible Assets | 663.5000 | 0.0000 | 29 | 284.3400 | 284.3400 | ||||||
| Long-Term Investments | 31.9000 | .1000 | - | - | 20.2760 | ||||||
| Fixed Assets | - | - | 788.1680 | 1,091.7220 | - | ||||||
| Inventories | 30.5000 | 14.1000 | 30.8480 | 57.2070 | 77.6040 | ||||||
| Accounts Receivable | 143.3000 | 85.5000 | 75.9640 | 177.6390 | 201.0830 | ||||||
| Cash and Cash Equivalents | 489.4000 | 569.3000 | 625.2590 | 714.7680 | 1,183.9450 | ||||||
| Current Assets | 1,589.6000 | 1,588.6000 | 1,546.5110 | 1,407.1530 | 1,831.5400 | ||||||
| Total Assets | 2,759.3000 | 2,319 | 2,334.6790 | 2,498.8750 | 2,896.7870 | ||||||
Liabilities
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 101.3000 | 49.3000 | 71.1940 | 74.9420 | 61.4510 | ||||||
| Long-term debt | - | - | 792.9350 | 739.3970 | 521.3350 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 280.6000 | 224 | 0.0000 | ||||||
| Provisions | 281.1000 | - | - | 110.4000 | 134.1000 | ||||||
| Liabilities | 1,563.4000 | 962.6000 | 1,238.4960 | 1,405.2470 | 1,558.5960 | ||||||
| Share Capital | - | - | 2.3850 | 2.4270 | 2.4500 | ||||||
| Total Equity | 1,195.9000 | 1,356.4000 | 1,096.1830 | 1,093.6280 | 1,338.1910 | ||||||
| Minority Interests | 196.7000 | 0.0000 | 21.1770 | 153.6610 | 181.6090 | ||||||
| Total liabilities equity | 2,759.3000 | 2,319 | 2,334.6790 | 2,498.8750 | 2,896.7870 | ||||||
Income Statement
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,527 | 1,212 | 580.4150 | 1,032.3360 | 1,702.1770 | ||||||
| Depreciation (total) | - | - | 63.2570 | 62.3430 | 61.3980 | ||||||
| Operating Result | 2.3000 | -903.4000 | -692.4120 | -466.8790 | 9.9360 | ||||||
| Interest Income | -14.8000 | -22.7000 | 72.8630 | 84.2060 | 81.4320 | ||||||
| Income Before Taxes | -12.4000 | -976.1000 | -734.8750 | -557.8000 | -67.3660 | ||||||
| Income Taxes | 38.8000 | -288.6000 | 6.9580 | 30.3810 | 16.6650 | ||||||
| Minority Interests Profit | -55.9000 | 242.5000 | 4.1900 | 31.8470 | -28.0210 | ||||||
| Net Income | -107 | -445 | -738.5550 | -556.3340 | -112.0520 | ||||||
Per Share
Cash Flow
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 267.8000 | -51.6000 | -513.1990 | -365.4320 | 236.1030 | ||||||
| Cash Flow from Investing Activities | -425.8000 | -54.1000 | 73.9590 | 268.8560 | 104.4690 | ||||||
| Cash Flow from Financing | 172.2000 | 180.9000 | 497.3760 | 188.9190 | 133.2710 | ||||||
| Decrease / Increase in Cash | 14.1000 | 79.9000 | 55.9600 | 89.5090 | 469.1770 | ||||||
| Employees | 2,200 | 1,800 | 1,830 | 1,950 | 2,150 | ||||||
